A 3-months Randomized, Placebo-controlled, Parallel Group, Double-blinded, Multi-centre, Phase I Study to Assess Tolerability and Safety of AADvac1 Applied to Patients With Mild-Moderate Alzheimer's Disease With 3-months Open Label Extension

Trial Profile

A 3-months Randomized, Placebo-controlled, Parallel Group, Double-blinded, Multi-centre, Phase I Study to Assess Tolerability and Safety of AADvac1 Applied to Patients With Mild-Moderate Alzheimer's Disease With 3-months Open Label Extension

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs AADvac 1 (Primary) ; Aluminium hydroxide
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Sponsors Axon Neuroscience
  • Most Recent Events

    • 10 Dec 2016 Results published in the AXON Neuroscience Media Release.
    • 18 Mar 2016 Results published in AXON Neuroscience media release.
    • 11 Nov 2015 According to an AXON Neuroscience media release, the results of this study were presented at the 8th International Conference on Clinical Trials in Alzheimers Disease (CTAD) 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top